View all CFS CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3.0 Contact Hours.

Resources

PER Pulse™ Recap
for Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspective on case management decisions is provided in these summaries.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas Pharma, AstraZeneca, Boston Biomedical Pharma, Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc, Lilly, Merck & Co, Inc, Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc, and Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®


Release Date: February 19, 2016
Expiration Date: February 19, 2017
Media: Internet - based

Activity Overview

The optimal care of patients with cancer is rapidly changing as a result of advances in all state-of-the-art cancer care, and continues to evolve due to advances in all aspects of patient care, including diagnosis and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular-targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® (CFS) has brought together over 2000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 33 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual CFS, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty provided continued insights on new developments in cancer therapeutics, and offered oncology professionals an opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of controlling and curing cancer.

This activity contains a series of clinical vignettes--focused on myeloma, chronic lymphocytic leukemia, lung cancer, and breast cancer--that illustrate the application of data and expert insights from the 2015 CFS in realistic case scenarios that reinforce key learning points from the conference, and facilitate application of these findings to clinical practice to improve patient care.

CME Activity Table of Contents

  • Case 1: Newly-diagnosed multiple myeloma
    Sagar Lonial, MD
  • Case 2: Newly diagnosed chronic lymphocytic leukemia Newly-diagnosed multiple myeloma
    Susan M. O’Brien, MD
  • Case 3: Metastatic non-small cell lung cancer: adenocarcinoma
    Heather A. Wakelee, MD
  • Case 4: Metastatic non-small cell lung cancer: squamous cell carcinoma
    Naiyer A. Rizvi, MD
  • Case 5: Neoadjuvant Therapy for Triple-Negative Breast Cancer
    Debu Tripathy, MD
  • Case 6: Germline testing for triple-negative breast cancer
    Mark E. Robson, MD

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, and nurse practitioners interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Describe landmark clinical trial results that provide the rationale for current and evolving treatment paradigms in hematologic and solid tumor management
  • Explain histologic, genomic, molecular, and patient-specific methods to stratify risk and personalize care for patients with cancer
  • Evaluate evolving chemotherapeutic, targeted, and immuno-oncology strategies in the context of key clinical trial data
  • Determine proactive approaches to mitigate predictable treatment-related adverse events, monitor efficacy, and optimize effectiveness of care along the disease continuum in the management of a variety of tumors
  • Consider the impact of recent clinical trial findings on current and evolving treatment paradigms

Faculty, Staff, and Planners' Disclosures

Faculty

Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA
Consultant: Novartis, Onyx, Millennium, Bristol-Myers Squibb, Sanofi, Celgene, Janssen
 

Susan M. O'Brien, MD
Associate Director for Clinical Science,
Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials and Research
UC Irvine Health
Orange, CA
Grant/Research Support: Acerta, TG Therapeutics, Regeneron, Gilead, Pharmacyclics, ProNAi
Consultant: Amgen, Celgene
 

Naiyer A. Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
Consultant: Merck, Roche, Bristol-Myers Squibb, AstraZeneca
 

Mark E. Robson, MD
Medical Oncologist
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant: Pfizer, GE Health
Other: Institutional Research Support: AbbVie, AstraZeneca, Biomarin
 

Debu Tripathy, MD
Professor and Chair,
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Grant/Research Support: Merrimack Pharmaceuticals, Novartis
Consultant: Merck, Nektar, Novartis
 

Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
Grant/Research Support: Novartis, Bristol-Myers Squibb, Clovis, Xcovery, Celgene, Roche/Genentech, MedImmune, Pfizer, Lilly
Consultant: Peregrine, Novartis, ACEA


The following individuals have no relevant financial relationships with commercial interests:
The staff of Physicians' Education Resource®, LLC.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By